How much weight can I lose on Wegovy or Ozempic?

In the STEP-1 trial, semaglutide 2.4mg (Wegovy) produced a mean ~14.9% body weight loss at 68 weeks vs ~2.4% with placebo. Ozempic 1mg (lower dose, type 2 diabetes indication) typically yields ~6–7%. Individual response varies — about a third of patients are 'super-responders' losing 20%+; about 15% lose under 5%.

How does Mounjaro / Zepbound compare?

Tirzepatide (Mounjaro for diabetes, Zepbound for weight loss) is a dual GIP+GLP-1 agonist. SURMOUNT-1 showed mean ~22.5% weight loss at 15mg over 72 weeks — roughly 50% more than semaglutide. Wegovy HD 7.2mg (FDA approved Mar 2026) narrows the gap to ~18%. Tirzepatide remains the most effective FDA-approved GLP-1 for weight loss.

What's the typical weight loss timeline?

Loss usually starts within 4 weeks. Most patients reach about 30% of their total loss by month 3, 60% by month 6, 85% by month 12 and plateau by month 15–18. Speed depends on starting weight, dose, adherence, diet and exercise. Stopping the drug generally leads to ~⅔ of the lost weight returning within a year (STEP-4 extension data).

Do I lose muscle on GLP-1s?

Body composition studies show roughly 25–40% of weight lost on GLP-1s is lean tissue — higher than diet alone (typically 20–25%). To minimise muscle loss, hit 1.6–2.2 g/kg protein daily, perform resistance training 2–3× per week, and avoid aggressive deficits. See our Protein Intake Calculator for targets.

Is this calculator a substitute for medical advice?

No. This is an educational tool using published clinical trial averages. GLP-1 medications are prescription drugs with side effects, contraindications (personal/family history of medullary thyroid carcinoma, MEN2, pancreatitis) and interactions. Always work with a licensed prescriber and never source these drugs from unregulated suppliers.

💉 GLP-1 Vægt Loss Lommeregner

Project your expected weight loss at 3, 6, 12 and 18 months on Wegovy, Ozempic, Mounjaro, Zepbound, Saxenda or Wegovy HD using published clinical trial averages.

Enheder

Current Vægt (kg)

Højde (cm)

Medicin & Dosis

Tilhørensprofil

⚠️ Uddannelsesværktøj — ikke medicinsk rådgivning. Fremskrivninger bruger gennemsnitlige forsøgsresultater; individuelle svar varierer meget (5%–25%+). GLP-1-lægemidler kræver recept og har alvorlige kontraindikationer, inklusiv personlig/familiehistorie med medulært thyreoideakarcinom, MEN2 og pankreatitis. Drøft med en autoriseret kliniker. Skaff aldrig fra uregulerede leverandører.

How GLP-1 Receptor Agonists Drive Vægt Loss

GLP-1-agonister efterligner det naturlige tarmhormon glucagon-like peptide 1. De sænker gastrisk tømning, undertrykker appetitten via hypothalamus og forbedrer insulinfølsomheden. Resultatet for de fleste patienter er dramatisk reduceret madindtag uden viljestyrketræt — typisk 20–35% færre daglige kalorier uden bevidst restriktioner.

Hvad de kliniske forsøg viser

STEP-1 (Wegovy 2.4mg): mean −14.9% body weight at 68 weeks vs −2.4% placebo
STEP-UP (Wegovy HD 7.2mg, FDA approved Mar 2026): mean ~−18% at 72 weeks
SURMOUNT-1 (Zepbound 15mg): mean −22.5% at 72 weeks; 57% of patients lost ≥20%
SCALE (Saxenda 3.0mg): mean −8% at 56 weeks
Retatrutide Phase 2: mean −24% at 48 weeks (still in development)

Tabtrajektorie

Loss is non-linear. About 30% of total loss happens by month 3, 60% by month 6, 85% by month 12, with most patients plateauing between months 15–18. The plateau occurs because metabolic adaptation reduces TDEE and the drug's anorectic effect partially offsets at lower body weight.

Vedligeholdelse og ophør

STEP-4 viste, at skift fra aktivt lægemiddel til placebo i uge 20 fik patienter til at regain about ⅔ of lost weight inden for det næste år. Nuværende evidens antyder, at GLP-1'er bedst betragtes som langtidsterapi for kronisk fedme, ikke et kortvarigt forløb. Livsstilsarbejde (styrketræning, højprotein-kost) gør vedligeholdelse efter eventuel ophør mere holdbar.

Bivirkninger

Most common: nausea (~40%), constipation, fatigue, decreased appetite — usually worst in the first 4–8 weeks of dose escalation and typically improves with slower titration. Rare but serious: pancreatitis, gallstones, gastroparesis, kidney injury via dehydration. Black-box warning for thyroid C-cell tumours (MTC) — contraindicated if personal or family history of MTC or MEN2.

Protect Your Lean Masse

Roughly 25–40% of GLP-1 weight loss is lean tissue — higher than diet alone. To minimise muscle loss while on GLP-1s:

Nå 1.6–2.2 g/kg protein pr. dag (brug vores Protein Intake Calculator)
Perform resistance training 2–3× per week
Undgå aggressivt kalorieunderskud – lad medicinen gøre arbejdet
Spor body composition (DEXA, BIA) every 3–6 months, not just scale weight

⚠️

Vigtig bemærkning: Dette er et uddannelsesprojektionsværktøj. GLP-1-receptoragonister er receptpligtige lægemidler med væsentlige risici, inklusiv pankreatitis, galdesygdom, nyreskade og en advarsel om thyreoideacellecancer. Arbejd altid med en autoriseret ordinerende læge, få din fulde sygehistorik gennemgået og skaff aldrig disse lægemidler fra uregulerede sammensætningsapoteker eller gråmarkedets online sælgere.

Relaterede lommeregnere

Semaglutide & Tirzepatide Dose — mg → units conversion for compounded vials on a U-100 syringe + titration schedule.
BMI Calculator — Kropsmasseindeks Index with WHO health context.
Calorie Deficit Calculator — Daglig calorie target to reach a goal weight. BMR + TDEE, weeks-to-goal projection and macro split.